The assessment of the plasmatic IL-6 concentration of MS patients represented a higher level prior to antioxidant treatment compared to the healthy group (+238%), and the statistical analysis of the data were significant (Figure 4A). The gene discussed is IL6; the disease is myeloid sarcoma.